{
  "id": 5874289,
  "title": "Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.",
  "url": "https://urgent.news/2026/09/06/viking-therapeutics-trades-well-below-its-wall-street-targets-heres",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-06T00:00:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/05/viking-therapeutics-trades-well-below-its-wall-str/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "The consensus price target for Viking Therapeutics (NASDAQ: VKTX) stands at around $92, suggesting a potential 162% increase from its current stock price. While this presents an appealing investment opportunity, skeptics question whether it is justified. The stock's success hinges on its lead drug, VK2735, a dual GLP-1 and GIP agonist being developed for obesity and type 2 diabetes. VK2735 boasts two potential advantages over competitors: a steeper rate of weight loss and a unique dual-formulation therapy (oral and subcutaneous). The dual formulation could allow patients to achieve substantial weight loss through a subcutaneous dose, followed by a more convenient oral maintenance treatment. These attributes could help VK2735 capture market share in a highly competitive landscape. Investors are eagerly awaiting the results of its Phase 3 trials for VK2735's subcutaneous formulation, expected in the second half of 2027, and the oral formulation slated to begin later this year, with results anticipated in 2028/2029. Moreover, the company is set to release the preliminary findings of a small Phase 1 maintenance trial involving 180 adults to assess optimal dosing regimens.",
  "summary": "Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.",
        "url": "https://urgent.news/2026/09/06/viking-therapeutics-trades-well-below-its-wall-street-targets-heres-5875632",
        "published": "2026-09-06T00:20:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}